Joint Injections for Osteoarthritic Knee Pain

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00085722
First received: June 14, 2004
Last updated: October 30, 2012
Last verified: October 2012

June 14, 2004
October 30, 2012
July 2004
July 2013   (final data collection date for primary outcome measure)
Quality of life, pain scores and disability at wks 0, 5, 9, 12, 24, 52 [ Time Frame: Participants will be followed for one year. ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00085722 on ClinicalTrials.gov Archive Site
Secondary outcomes include disease and general quality of life indicators (all subjects) and magnetic resonance image (in a subset of 37 subjects). [ Time Frame: Participants will be monitored for one year. ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
Joint Injections for Osteoarthritic Knee Pain
The Efficacy of Prolotherapy in Osteoarthritic Knee Pain

The purpose of this study is to determine whether prolotherapy (PrT), a therapy based on injection of a sugar solution in and around the knee, can decrease pain and disability from knee osteoarthritis (OA).

OA is a common, debilitating condition for which there is no cure and no known cause. Prolotherapy (PrT) is an injection-based therapy for chronic musculoskeletal pain in which an irritant solution is injected at painful ligaments and tendons to produce stronger connective tissue and decrease pain. Although limited studies suggest PrT is effective may be effective for low back pain, its use has not been rigorously studied in human clinical trials for osteoarthritis.

Participants in this study will be randomly assigned to receive one of three treatments: standard PrT, injections with a saline placebo, or a pamphlet with recommendations for home knee physical therapy. Injections will be given at Weeks 1, 5, and 9; injection group subjects will have the option to receive an additional 2 sets of injections. All participants will be assessed for a total of 1 year. A set of disease-specific and general quality-of-life questionnaires will be used to assess participants' outcomes . A randomized subset of participants (N=38)will receive magnetic resonance imaging (MRI)of the knee at baseline and 52 weeks. At study completion, participants who did not receive PrT will have the option to receive up to five sessions of PrT at no cost. Data will be collected for this group (minus MRI) and will be analyzed separately. Enrollment is limited to residents of Southern Wisconsin.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Osteoarthritis
  • Procedure: Dextrose Prolotherapy
    Injection procedure: 50% dextrose is diluted with .9% 'normal' saline and 1% lidocaine to achieve 15% dextrose for ligament injections and 25% dextrose for intra-articular injection.
    Other Name: Dextrose
  • Procedure: Saline Prolotherapy
    7 mL 9% 'normal' saline and 3mL 1% lidocaine
    Other Name: Saline
  • Other: At-home physical therapy exercise group
    Subjects in the at-home physical therapy exercise group will receive a patient information pamphlet about knee osteoarthritis and conservative care instructions for standard at-home physical therapy exercises
    Other Name: Exercise
  • Experimental: Dextrose
    Subjects in Group 1 receive PrT with 15% and 25% dextrose solution, as it is generally practiced in the US today.
    Intervention: Procedure: Dextrose Prolotherapy
  • Placebo Comparator: Normal saline
    Subjects in Group 2 will receive the same treatment as Group 1, except that a 0.9% 'normal' saline solution with no known benefit will be used instead of dextrose.
    Intervention: Procedure: Saline Prolotherapy
  • Exercise
    At-home physical therapy exercises as a non-injection control
    Intervention: Other: At-home physical therapy exercise group

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
111
July 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pain from knee osteoarthritis that has impacted life for 3 months to 10 years
  • X-ray results indicating knee osteoarthritis

Exclusion Criteria:

  • Knee osteoarthritis surgical candidate
  • History of total knee joint repair
  • Prior use of PrT
  • Prior fracture of the knee joint
  • Joint injection of steroids or other drugs within the past 3 months
  • Rheumatoid or inflammatory arthritis
  • Chronic use of narcotic medication
  • Other chronic pain diagnoses
  • diabetes mellitus
  • Body mass index (BMI) greater than 45
  • Unresolved litigation
  • Pregnancy
  • Co-morbidity that may interfere with the study
Both
40 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00085722
K23 AT001879-01, K23AT001879-01
Yes
University of Wisconsin, Madison
University of Wisconsin, Madison
National Center for Complementary and Alternative Medicine (NCCAM)
Principal Investigator: David P. Rabago, MD University of Wisconsin Dept of Family Medicine
University of Wisconsin, Madison
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP